Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 8/20 | 0.48 |
| ▸ | VNN1 | O95497 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | ALOX5AP | P20292 | 4/20 | 0.36 |
| ▸ | FEN1 | P39748 | 4/20 | 0.36 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.36 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.35 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.35 |
| ▸ | METAP2 | P50579 | 1/20 | 0.35 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.34 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30479230 | 1.00 | ESR1 (0.48) | ESR1VNN1THRBALOX5APFEN1 | |
| SCHEMBL25332395 | 0.89 | ESR1 (0.39) | ESR1THRBALOX5APFEN1DEGS1 | |
| SCHEMBL30479246 | 0.89 | ESR1 (0.39) | ESR1THRBALOX5APFEN1DEGS1 | |
| SCHEMBL25967153 | 0.86 | ESR1 (0.40) | ESR1ALOX5APFEN1 | |
| SCHEMBL25953879 | 0.85 | ESR1 (0.39) | ESR1ALOX5APFEN1 | |
| SCHEMBL30604773 | 0.84 | ESR1 (0.49) | ESR1 | |
| SCHEMBL25953323 | 0.84 | ESR1 (0.49) | ESR1 | |
| SCHEMBL30604770 | 0.83 | ESR1 (0.49) | ESR1 | |
| SCHEMBL25952542 | 0.83 | ESR1 (0.49) | ESR1 | |
| SCHEMBL25952543 | 0.83 | ESR1 (0.48) | ESR1ALOX5APFEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12128040-B2 | Selective estrogen receptor degraders | ELI LILLY AND COMPANY (US) | 2024-10-29 | — | — | US | disclosed |
| US-20240199629-A1 | PROCESSES FOR THE PREPARATION OF SELECTIVE ESTROGEN RECEPTOR DEGRADERS | ELI LILLY AND COMPANY | 2024-06-20 | — | — | US | disclosed |
| US-11926634-B2 | Processes for the preparation of selective estrogen receptor degraders | ELI LILLY AND COMPANY (US) | 2024-03-12 | — | — | US | disclosed |
| WO-2024042157-A1 | NOVEL SUBSTITUTED QUINOLINE AND TETRAHYDRONAPHTHALENE CARBOXYLIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF | SANOFI (FR) | 2024-02-29 | — | — | WO | disclosed |
| CN-112424205-B | Selective estrogen receptor degrading agents | 伊莱利利公司 | 2023-10-31 | — | — | CN | disclosed |
| WO-2023150056-A1 | PROCESSES FOR THE PREPARATION OF SELECTIVE ESTROGEN RECEPTOR DEGRADERS | ELI LILLY AND COMPANY (US) | 2023-08-10 | — | — | WO | disclosed |
| WO-2023150056-A1 | PROCESSES FOR THE PREPARATION OF SELECTIVE ESTROGEN RECEPTOR DEGRADERS | ELI LILLY AND COMPANY (US) | 2023-08-10 | — | — | WO | disclosed |
| US-20230242545-A1 | PROCESSES FOR THE PREPARATION OF SELECTIVE ESTROGEN RECEPTOR DEGRADERS | ELI LILLY AND COMPANY | 2023-08-03 | — | — | US | disclosed |
| US-20230242545-A1 | PROCESSES FOR THE PREPARATION OF SELECTIVE ESTROGEN RECEPTOR DEGRADERS | ELI LILLY AND COMPANY | 2023-08-03 | — | — | US | disclosed |
| US-20230242545-A1 | PROCESSES FOR THE PREPARATION OF SELECTIVE ESTROGEN RECEPTOR DEGRADERS | ELI LILLY AND COMPANY | 2023-08-03 | — | — | US | disclosed |
| EP-3820874-B1 | SELECTIVE ESTROGEN RECEPTOR DEGRADERS | LILLY CO ELI (US) | 2022-11-30 | — | — | EP | disclosed |
| EP-3820874-B1 | SELECTIVE ESTROGEN RECEPTOR DEGRADERS | LILLY CO ELI (US) | 2022-11-30 | — | — | EP | disclosed |
| EP-3820874-A1 | SELECTIVE ESTROGEN RECEPTOR DEGRADERS | Eli Lilly and Company (US) | 2021-05-19 | — | — | EP | disclosed |
| CN-112424205-A | Selective estrogen receptor degraders | 伊莱利利公司 | 2021-02-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199629-A1 | PROCESSES FOR THE PREPARATION OF SELECTIVE ESTROGEN RECEPTOR DEGRADERS | ESR1, GPER1, ESRRA | ESR1 1/4885VNN1 3484/4885THRB 490/4885 |
| US-20230242545-A1 | PROCESSES FOR THE PREPARATION OF SELECTIVE ESTROGEN RECEPTOR DEGRADERS | ESR1, GPER1, ESRRA | ESR1 1/4885VNN1 3484/4885THRB 490/4885 |
| US-11926634-B2 | Processes for the preparation of selective estrogen receptor degraders | ESR1, GPER1, ESRRA | ESR1 1/4885VNN1 3484/4885THRB 490/4885 |
| US-12128040-B2 | Selective estrogen receptor degraders | ESR1, GPER1, ESR2 | ESR1 1/4885VNN1 1793/4885THRB 90/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.